Anzeige
Mehr »
Login
Samstag, 19.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Die 3-Milliarden-Dollar-Frage: Wird Foremost das nächste Denison?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
462 Leser
Artikel bewerten:
(1)

Yili Group: Yili Achieves Double-Digit Growth in Revenue and Net Profit in H1 FY2021

- Yili exceeds market expectations with double-digit growth in revenue and net profit in H1 FY2021.

- Yili's strong financial performance reflects efforts at innovation and improvement of products, distribution channels, and global network.

HOHHOT, China, Sept. 1, 2021 /PRNewswire/ -- On August 30th, Yili - Asia's leading dairy company - released its FY2021 H1 financial report. The company exceeded market expectations with double-digit growth in revenue and net profit, with gross revenue rising 18.89% YoY to reach RMB 56.506 billion, and net profit attributable to the parent company jumping 42.48% YoY to reach RMB 5.322 billion.

On August 30th, Yili released its FY2021 H1 financial report. The company exceeded market expectations with double-digit growth in revenue and net profit, with gross revenue rising 18.89% YoY to reach RMB 56.506 billion, and net profit attributable to the parent company jumping 42.48% YoY to reach RMB 5.322 billion.

Yili's interim results set another new high for the Asian dairy industry, as the latest data makes Yili the first likely dairy company in Asia to exceed RMB 100 billion in revenue. Strong financial performance in H1 FY2021 also suggests that the company will likely continue to maintain its momentum.

Further market expansion for core products

In the first half of 2021, the dairy industry faced significant challenges from global economic and trade instability and rising costs for raw materials. However, Yili exceeded its operation targets for the period by leveraging its competitive advantages across the whole industry value chain.

During the reporting period, Yili's main products continued to exhibit strong growth. For instance, the total sales revenue for Satine, AMBPOMIAL, Changqing, Jinlingguan, and Chocliz increased by 20.7% YoY. In particular, the AMBPOMIAL AMX Zero Sugar yoghurt and AMBPOMIAL 5G-Protein yoghurt series, launched in the second half of 2020, saw rapid growth and great brand development potential. Meanwhile, the sales revenue of new product categories represented by Satine A2 Beta-casein Organic Pure Milk, Yili Zhennong High-calcium Milk, Changqing Tea & Fruit Yogurt, and Cute Star Child Growth Goat Milk accounted for 15.6% of Yili's total revenue and became essential contributors to Yili's performance.

Extending and diversifying product lines

During the reporting period, the retail sales of cheese products more than doubled year over year, giving the company a head start in the segment with high growth potential.

The company's low-temperature milk business also grew fast, with 5.7% increase in market share.

Yili's Jinlingguan series of high-end infant formula, developed with support from nineteen years of breast milk research and high-quality milk sources such as organic and A2 milk, is also widely recognized as a reliable and good-quality product in the market. Nielsen retail data showed the retail sales of infant formulas increased by 35.2% YoY, in which the growth rate of Jinlingguan Zhenhu reached 37% to become the fastest-growing brand in its segment.

In the non-dairy category, Yili's Inikin Yike mineral water also made a breakthrough in sales growth and has mainly been distributed in big cities through e-commerce, O2O home delivery, and other channels. Manufacturing plants for the product are now operating at full capacity.

Upgrading distribution channels and strengthening the global network

The ongoing impact of COVID-19 has affected consumption behaviors and scenarios. Of note, there has been an accelerated growth in the contributions of new retail and e-commerce to the total retail sales of consumer goods.

While leveraging existing advantages in its distribution channels, Yili also embraced digital channels in response to the latest market trends. Yili's e-commerce business grew 21.8% YoY in the first half of 2021, contributing to the high market penetration rate of 85.7% for its UHT milk.

In addition, Yili also leveraged synergy within its "global supply chain network" to ensure the efficient operation of its supply, production, and marketing systems. As of June 2021, the company's total production capacity neared 13.94 million tons per year.

In August this year, Rabobank released its annual Global Dairy Top 20 list, in which Yili Group was again listed among the top five global dairy companies. Yili was also ranked as the leading company in Asia for eight consecutive years.

Image Attachments Links:

Link: http://asianetnews.net/view-attachment?attach-id=399569

Caption: On August 30th, Yili released its FY2021 H1 financial report. The company exceeded market expectations with double-digit growth in revenue and net profit, with gross revenue rising 18.89% YoY to reach RMB 56.506 billion, and net profit attributable to the parent company jumping 42.48% YoY to reach RMB 5.322 billion.

Photo - https://mma.prnewswire.com/media/1606498/Yili_growth.jpg

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.